Moderna, Inc. (NASDAQ:MRNA) has begun paying into a March 2026 up-to-$2.25B LNP patent settlement—$178M on July 8 covering Arbutus’s share and litigation costs—while facing a separate patent suit from Sanofi over Translate Bio mRNA/LNP tech tied to COVID-19 vaccines.
Previous Week Recap
- Moderna $178M Payment, LNP Patent Settlement: Moderna (MRNA) paid about $178M on July 8 as part of a March 2026 up-to-$2.25B settlement over LNP patents; $178M covers Arbutus’s share and litigation cost reimbursement.
- Sanofi Sues Moderna Over mRNA/LNP Patents: Sanofi sued Moderna in New Jersey, alleging infringement of Translate Bio mRNA/LNP patents tied to COVID-19 vaccines, seeking monetary damages; Moderna has not publicly commented.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.